NCT07073417Active, not recruitingPhase 2
A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)
A Multicenter, Randomized, Open-label, Treatment Switching Phase II Study to Evaluate the Efficacy and Safety of XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
The aim of the study is to compare the efficacy and safety of XW003 injection versus semaglutide injection in Chinese adults with obesity
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 163 (actual)
- First submitted
- 9 Jul 2025
- Start date
- 28 Jul 2025
- Primary completion date
- 27 Feb 2027
- Lead sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Diseases
- Obesity
- NCT number
- NCT07073417
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 163
- From 28 Jul 2025 to the primary completion date, 27 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have used any weight-loss drugs, hypoglycemic drugs, or drugs that may cause significant weight gain within 3 months prior to screening.
Other illness
- Diagnosis of obesity due to endocrine disorders or a single gene mutation, including but not limited to hypothalamic obesity, pituitary obesity, Cushing's syndrome, hypothyroidic obesity (except for those with normal thyroid function at screening and expected to remain unchanged throughout the trial period after at least 3 months of thyroid hormone replacement therapy), insulinoma, acromegaly.
- History of bariatric surgery or planning to undergo bariatric surgery or use other weight-loss drugs or devices during the trial (except acupuncture for weight loss, liposuction, or abdominal fat removal for more than one year before screening; Except the removal or expulsion of the airbag in the stomach for more than 1 year before screening.
- Diagnosis with any type of diabetes (except gestational diabetes).
- History of acute or chronic pancreatitis or pancreatic injury, history of symptomatic gallbladder disease (except cholecystectomy).
- History of clinically significant gastric emptying abnormalities, such as gastroparesis or gastric outlet obstruction.
Who the study is looking for
- BMI≥30 kg/m2 at screening, waist circumference ≥90 cm for men and ≥85 cm for women.
- Weight change of less than 5% within 3 months prior to screening (self-reported).
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University People's Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.